Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
about
A high-throughput cidality screen for Mycobacterium tuberculosisMethyl-hydroxylamine as an efficacious antibacterial agent that targets the ribonucleotide reductase enzymeIdentification of New Molecular Entities (NMEs) as Potential Leads against Tuberculosis from Open Source Compound RepositoryBiochemical and structural investigations on phosphoribosylpyrophosphate synthetase from Mycobacterium smegmatisImmunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in miceOrganism-specific rRNA capture system for application in next-generation sequencingA High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis.Crystal structures of Mycobacterial MeaB and MMAA-like GTPases.Evaluation of pseudopteroxazole and pseudopterosin derivatives against Mycobacterium tuberculosis and other pathogens.Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening.Role of Cathepsins in Mycobacterium tuberculosis Survival in Human Macrophages.Synthesis and evaluation of functionalized benzoboroxoles as potential anti-tuberculosis agents.Whole-cell screening-based identification of inhibitors against the intraphagosomal survival of Mycobacterium tuberculosis.Engineering mycobacteria for the production of self-assembling biopolyesters displaying mycobacterial antigens for use as tuberculosis vaccine.Challenges and opportunities in developing novel drugs for TB.The future for early-stage tuberculosis drug discoveryBiophysical Screening of a Focused Library for the Discovery of CYP121 Inhibitors as Novel Antimycobacterials.Evaluation of bactericidal and anti-biofilm properties of a novel surface-active organosilane biocide against healthcare associated pathogens and Pseudomonas aeruginosa biolfilm.In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains.Plants in our combating strategies against Mycobacterium tuberculosis: progress made and obstacles met.Diphenyleneiodonium chloride (DPIC) displays broad-spectrum bactericidal activity.Screening of anti-mycobacterial compounds in a naturally infected zebrafish larvae model.Rv2629 Overexpression Delays Mycobacterium smegmatis and Mycobacteria tuberculosis Entry into Log-Phase and Increases Pathogenicity of Mycobacterium smegmatis in Mice.Hit Generation in TB Drug Discovery: From Genome to Granuloma.Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections.Homo- and heteroleptic bismuth(III/V) thiolates from N-heterocyclic thiones: synthesis, structure and anti-microbial activity.Protective immune mechanisms of Yifei Tongluo, a Chinese herb formulation, in the treatment of mycobacterial infectionThe role of modern drug discovery in the fight against neglected and tropical diseases
P2860
Q28543482-F282AAFE-16AC-4505-84B9-28F4A0977DA0Q28544447-AB4B267B-2C1D-4727-89EC-E96C80F2689FQ28551394-4F97AB5B-7E1F-4841-BA69-AFB6078FCA10Q33574593-8FACF862-76F0-40E9-90C3-9D96446896D6Q34271591-ABAD773E-DF87-4031-9D61-6E8A42BA00FDQ35000646-EA0EF492-73E4-4A56-8F9B-C8F618061D01Q35670579-3A283ED4-848E-42C3-B39B-2EE388B1BEE5Q36244626-CCC34D52-D73A-4200-ADC5-AED3D16DDF9BQ36248387-76542EC0-46E4-45DB-9AC5-345309B63041Q36575914-75097955-7CB2-4F11-B392-3F01F40C0309Q37215806-F726AB31-208A-41A2-9468-3A63116BD6D3Q37252783-1E0927A4-FAF3-45B8-8619-DFC50C9FFE5FQ37335738-E4F0F42F-65EB-4B99-938B-DE432CD8CC37Q37644063-0E25C82F-0688-4558-B47B-CD41B1256A5FQ37924294-A0D98B89-13C9-4951-8A9E-92C629E2FE1DQ38358621-D43CB637-BE17-423A-B7A8-9B42D753C720Q38620801-A100424F-5506-4397-8358-3AFA9B071512Q38634922-E14AA282-B06D-4D19-A330-BC7BB84B169DQ38650879-1F2A65BE-E7E5-4A3D-A4D9-D6E47DADFA20Q38733962-3DA92A6D-3C10-4C90-B4BE-0D30CB26A8E6Q40045003-FC11C465-73B8-4532-99E0-50AA10F20AE6Q40474339-084721B3-4841-437D-8A18-1A931EDE69DEQ47169708-CC865403-14B6-4E09-B389-D90249D959DCQ47702665-090A545F-8428-4D30-95B8-DC6481DD8A43Q50271090-BDFD3EA0-F673-456A-AD7C-3FE92B657D88Q54281555-37260BE3-D2F3-4D94-A510-96FFE99D5FFEQ58752243-E252B00B-D267-41A5-87AE-828D717E24AFQ58854103-CDF9376D-DB48-436F-82F2-3B85A57878FD
P2860
Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of the Mycobacteriu ...... erium tuberculosis inhibitors.
@ast
Evaluation of the Mycobacteriu ...... erium tuberculosis inhibitors.
@en
type
label
Evaluation of the Mycobacteriu ...... erium tuberculosis inhibitors.
@ast
Evaluation of the Mycobacteriu ...... erium tuberculosis inhibitors.
@en
prefLabel
Evaluation of the Mycobacteriu ...... erium tuberculosis inhibitors.
@ast
Evaluation of the Mycobacteriu ...... erium tuberculosis inhibitors.
@en
P2093
P1433
P1476
Evaluation of the Mycobacteriu ...... erium tuberculosis inhibitors.
@en
P2093
Christopher H Miller
David S Bellows
Mudassar Altaf
P304
P356
10.1016/J.TUBE.2010.09.002
P577
2010-10-12T00:00:00Z